Squarepoint
GLMD icon

Squarepoint’s Galmed Pharmaceuticals GLMD Stock Holding History

Squarepoint’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-18
Closed -$71K – 3289
2021
Q3 		$71K Sell
18
-5
-22% -$21K ﹤0.01% 2732
2021
Q2 		$99K Sell
23
-15
-39% -$65.2K ﹤0.01% 3015
2021
Q1 		$188K Buy
38
+23
+153% +$127K ﹤0.01% 2720
2020
Q4 		$65K Sell
15
-2
-12% -$9.99K ﹤0.01% 2776
2020
Q3 		$85K Buy
+17
New +$111K ﹤0.01% 2311
2020
Q2 		– Sell
-24
Closed -$119K – 2328
2020
Q1 		$119K Buy
24
+17
+243% +$129K ﹤0.01% 1606
2019
Q4 		$59K Buy
+7
New +$48.1K ﹤0.01% 2388
2019
Q1 		– Sell
-11
Closed -$110K – 2251
2018
Q4 		$110K Sell
11
-11
-50% -$154K ﹤0.01% 1786
2018
Q3 		$431K Buy
+22
New +$412K 0.01% 1371

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's GLMD Position: Q4 2021 in Review

Squarepoint sold out of Galmed Pharmaceuticals (GLMD) in Q4 2021, closing a stake of 18 shares — an estimated $71K sold.

Squarepoint first reported a position in GLMD in Q3 2018 and held it in 9 quarters. The position peaked at $431K in Q3 2018. 22 funds tracked by Wall St. Rank hold GLMD as of Q4 2021.

  • Squarepoint reported no remaining Galmed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Squarepoint sold 18 Galmed Pharmaceuticals shares in Q4 2021, an estimated $71K.
  • Squarepoint first reported a position in Galmed Pharmaceuticals in Q3 2018 and held it in 9 quarters.
  • Squarepoint's Galmed Pharmaceuticals position peaked at $431K in Q3 2018.
  • 22 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2021.

Based on Squarepoint's 13F filing for Q4 2021, filed 14 Feb 2022.